Abstract:With an increasing global incidence in children younger than the age of five, respiratory syncytial virus (RSV) is one of the most common viral respiratory infections worldwide. Despite the increasing number of cases among infants and young children, RSV can infect any age group; however, some individuals are more high risk than others. Premature infants, young children, elderly, and immunocompromised individuals are the most likely to suffer a more severe presentation of RSV in comparison to healthy adults. RSV is transmitted through respiratory droplets via direct contact with an infected individual or with contaminated surfaces. The viral genome of RSV consists of 11 proteins. Out of these 11, two proteins allow for the attachment of the virus to the respiratory epithelial cells and fusion with host cells. Upon fusion, the viral material transfers to the host cell, where viral replication occurs. It is important to acknowledge that an individual is considered infectious and can transmit the virus even before the symptomatic presentation of RSV begins. As long as the individual is shedding the virus, he or she is considered infectious. The length of viral shedding also differs depending on the severity of the infection, who is infected, and the underlying immune status of an individual. Currently, there is no definitive treatment for RSV; however, supportive therapy is considered the mainstay treatment. Some pharmaceutical treatments such as ribavirin have been FDA-approved; however, the administration is typically limited to children and infants. Palivizumab is also administered as an immune prophylaxis; however, both therapies are constantly at the end of a cost-effective debate due to their extensively expensive nature and questionable adverse effect profiles. Supportive therapy includes hydration, supplemental oxygen, and mechanical ventilation in hospitalized cases; however, most RSV cases can be treated as outpatient cases. Prevention techniques such as hand washing and maintaining social distancing are imperative to minimize the transmission of the virus as much as remotely possible.

Extracellular amoebal-vesicles: potential transmission vehicles for respiratory viruses

Respiratory Syncytial Virus

Microbiological and epidemiological features of respiratory syncytial virus

Respiratory syncytial virus infections: old challenges and new opportunities

Respiratory syncytial virus (RSV): a scourge from infancy to old age

Host Responses to Respiratory Syncytial Virus Infection

Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

Host Components Contributing to Respiratory Syncytial Virus Pathogenesis

Molecular epidemiology of respiratory syncytial virus transmission in childcare

Novel intercellular spread mode of respiratory syncytial virus contributes to neutralization escape

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment

The disease burden of respiratory syncytial virus in older adults

The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography

Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation

Research Progress in Respiratory Syncytial Virus Vaccines

Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons

Evolution of proteomics technologies for understanding respiratory syncytial virus pathogenesis

Respiratory syncytial virus-induced high mobility group box 1 secretion modulates innate immune response to promote inflammation

Role of Differences in Respiratory Syncytial Virus F and G Glycoproteins on Susceptibility to Inactivation by Antimicrobial Peptides LL-37 and Human Beta-Defensins